GlassScriptPhysician profile
Kimberly Ruhl
NPI 1205949567
$4,363.15
in general payments reported to CMS, 2019-2025
24 companies · $828 in 2025
The $828 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $264 · 2021: $463 · 2022: $731 · 2023: $1,052 · 2024: $1,024 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,377.21 | 2020-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $437.22 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.79 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $267.39 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $261.47 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Pfizer INC. | $250.55 | 2021-2025 | |
| Incyte Corporation | $237.05 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $177.62 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Biofrontera INC. | $162.41 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.58 | 2020-2025 | Cabtreo, Jublia |
| Revance Therapeutics, INC. | $119.23 | 2024-2025 | Daxxify |
| Janssen Biotech, INC. | $98.72 | 2021-2024 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $93.85 | 2020-2024 | Otezla |
| Genzyme Corporation | $77.02 | 2020-2025 | |
| Journey Medical Corporation | $73.98 | 2020-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $56.39 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.98 | 2022-2024 | Sotyktu |
| Fidia Pharma USA INC. | $34.71 | 2024 | |
| Leo Pharma INC. | $32.56 | 2022-2023 | Adbry |
| Almirall LLC | $31.32 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.37 | 2023-2025 | Spevigo |
| Sandoz INC. | $16.58 | 2020 | |
| Dermira, INC. | $14.58 | 2020 | |
| Epi Health, LLC | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ruhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.